New York, NY, June 25, 2021 (GLOBE NEWSWIRE) – IR-Med, Inc. (OTCPINK: IRME) today announced the appointment of Dr. Rom Eliaz as CEO.
Prior to his appointment as CEO, Dr Eliaz was Founder and Managing Director of Elrom Ventures, where he was also Managing Director of aMoon Fund. Previously, Dr Eliaz was in charge of the Merck ventures fund and bio-incubator in Israel, where he co-founded several companies of the incubator, vice president of innovative branding products at Teva and CEO of NasVax, a publicly traded company. and Immcure Therapeutics.
“We are delighted that a seasoned life sciences and medical device executive like Rom is joining us as CEO. Its scientific and financial experience will be decisive as we continue to implement our strategy of developing sensor-based medical devices, by developing point-of-service solutions for the early identification and surveillance of preventable chronic diseases ”, explained Oded Bashan, Chairman of the Board of IR-Med.
Commenting on his appointment as CEO, Rom Eliaz added: “I am incredibly excited and honored to join IR-Med. I believe that IR-Med is one of the companies which strives to modernize the care pathways by developing and integrating new sensor-based medical devices in the world in truly unmet medical needs, and to contribute actively to become the leader in these fields. I have the privilege of leading our mission-driven company into the next wave of growth. At IR-Med, we have a tremendous opportunity to leverage emerging technologies and data-driven insights to transform and sustainably manage long-term patient healthcare. “
Dr Eliaz has been an Assistant Professor at the University of California, San Francisco, has published over 40 scientific papers, and holds over 10 scientific patents in the areas of drug targeting and delivery, gene therapy, and gene therapy. tissue engineering.
Dr Eliaz obtained his PhD (cum-laude) in Chemical Engineering and Biotechnology from the Weizmann Institute and Ben-Gurion (BGU). His BSc and MSc, with honors, degrees in Chemical Engineering and Biotechnology are from BGU, and he holds an MBA from Harvard Business School and the Boston University Joint Program at BGU.
About RI–Med Ltd.
IR-Med Ltd is a developmental company currently focused on the development and application of infrared (IR) and artificial intelligence (AI) technologies to treat common medical conditions. Initially, IR-Med’s technologies are designed to treat the early detection of pressure ulcers (PIs) and the detection and diagnosis of ear infections, primarily in children. For more information, visit http://www.ir-medical.com.
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among others, references to new technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in forward-looking statements due to many factors. These factors include, among other things, our ability to raise the additional funds that we will need to continue our activities plan and product development plans; uncertainties inherent in the development of new products or technologies and in the operation of a business in the development phase; our ability to develop, conduct clinical trials, obtain approvals and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update any forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law. The Company does not undertake any obligation to publicly update any forward-looking statement. Neither the Company nor me.R MED are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Company details :